Favipiravir
- Generic Name
- Favipiravir
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4FN3O2
- CAS Number
- 259793-96-9
- Unique Ingredient Identifier
- EW5GL2X7E0
- Background
Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.
Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.
- Indication
⑴用于埃博拉病毒感染的治疗。
⑵用于治疗成人新型或再次流行的流感（仅限于其他抗流感病毒药物治疗无效或效果不佳时使用）
- Associated Conditions
- Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 168
- Registration Number
- NCT04501783
- Locations
- 🇷🇺
Medical center LLC "Neuroprofi", Korolev, Russian Federation
🇷🇺State budgetary institution of health care of the city of Moscow "City Clinical Hospital №52 of the Moscow City Healthcare Department", Moscow, Russian Federation
🇷🇺State budgetary institution of health care of the city of Moscow "City Clinical Hospital №67 n.a. LA Vorokhobova of the Moscow City Healthcare Department", Moscow, Russian Federation
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
- Conditions
- COVID-19
- Interventions
- Other: Lopinavir/ Ritonavir PlaceboOther: Favipiravir Placebo
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- University College, London
- Target Recruit Count
- 240
- Registration Number
- NCT04499677
- Locations
- 🇬🇧
Royal Free Hospital, London, United Kingdom
🇬🇧University College London Hospital (UCLH), London, United Kingdom
Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Genuine Research Center, Egypt
- Target Recruit Count
- 26
- Registration Number
- NCT04478448
- Locations
- 🇪🇬
Genuine Research Center GRC, Cairo, Egypt
Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults
- Conditions
- COVID-19
- Interventions
- Procedure: Curently used therapy for COVID-19 non-critical patientsDrug: Maraviroc+Favipiravir+CT
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Hospital General de México Dr. Eduardo Liceaga
- Target Recruit Count
- 19
- Registration Number
- NCT04475991
- Locations
- 🇲🇽
Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Cdmx, Mexico
Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Ministry of Health, Turkey
- Target Recruit Count
- 1000
- Registration Number
- NCT04474457
- Locations
- 🇹🇷
Hacettepe University, School of Medicine, Ankara, Turkey
Favipiravir Therapy in Adults With Mild COVID-19
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 231
- Registration Number
- NCT04464408
- Locations
- 🇸🇦
Prince Mohammed Bin Abdul Aziz Hospital - Al Madinah, Al Madinah, Saudi Arabia
🇸🇦King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia
🇸🇦Primary Health Care-Al Mansoura, Riyadh, Saudi Arabia
Control of COVID-19 Outbreaks in Long Term Care
- Conditions
- COVID-19SARS-CoV-2
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Appili Therapeutics Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT04448119
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Kocak Farma
- Target Recruit Count
- 30
- Registration Number
- NCT04444986
- Locations
- 🇹🇷
Novagenix Drug R&D Center, Akyurt, Ankara, Turkey
🇹🇷Farmagen Ar-Ge Biyot. Ltd. Sti., Gaziantep, Turkey
An Adaptive Clinical Trial of Antivirals for COVID-19 Infection
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 190
- Registration Number
- NCT04445467
- Locations
- 🇦🇺
Alfred Health, Melbourne, Victoria, Australia
An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Chromis LLC
- Target Recruit Count
- 330
- Registration Number
- NCT04434248
- Locations
- 🇷🇺
Yakutsk City Clinical Hospital, Yakutsk, Russian Federation
🇷🇺Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation
🇷🇺Infectious clinical hospital No.2 of Nizhny Novgorod, Nizhny Novgorod, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.